For many women, especially those struggling with perimenopausal weight gain and insulin resistance, GLP-1 receptor agonist medications (GLP-1s) have emerged as a promising treatment option
The FDA-approved injection sites for most of these medications include three primary areas: the abdomen, the front of the thighs, and the upper arms (though upper arm injections often require administration by another person)
Eli Lilly has announced positive topline results from two further Phase III trials of its investigational obesity treatment retatrutide , bringing the company closer to regulatory submission for the once-weekly triple hormone receptor agonist
Brunicardi FC, Shavelle DM, Andersen DK (1995) Neural regulation of the endocrine pancreas
The dosing flexibility available with compounded formulations including lower starting doses and custom titration increments can help providers manage GI side effects more effectively than fixed commercial dosing allows
In short, not very